Fremanezumab (Ajovy®) is accepted for restricted use within NHS Scotland

Source:
Scottish Medicines Consortium - SMC
Publisher:
Scottish Medicines Consortium
Publication date:
13 January 2020

Abstract

Fremanezumab is accepted for use in NHS Scotland for prophylaxis of migraine in adults who have at least four migraine days per month, restricted to patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.